Health outcomes data can be an important promotional/commercial tool for the biopharma industry, but approaches differ company to company as the marketplace continues to evolve. A new study by Best Practices, LLC examines internal and external uses of health outcomes data for promotional purposes.
The study found while a majority of organizations - 67 percent - use health outcomes data internally for pricing, only 45 percent utilize health outcomes data for pricing discussions with managed care companies. According to the same research, Medical Science Liaisons are the only group - compared here to sales reps and managed care account managers - commonly empowered to share off-label health outcomes data promotionally.
These insights represent just a small portion of the metric-driven data available in Best Practices in Utilizing Health Outcomes Data for Promotional/Commercial Efforts, new research that seeks to understand how pharmaceutical and biotech organizations use health outcomes data in promotional settings. The study also examined the pressing Regulatory issues raised by the different uses of health outcomes data.
Key topics covered in this research include:
- Structure and Reporting Lines of Authority
- Health Outcomes Decisions
- Use of Health Outcomes Data Proactively and Retrospectively
- Who and How is Health Outcomes Data Utilized with Different Groups
- Health Outcomes Review Process and Structure
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy